Supplementary Figure 2. Redin et al., 2020

A

Control

Dasatinib

Anti-PD-1

Dasatinib + Anti-PD-1

pSFKs

pSTAT3 (Y705)

STAT3

pERK1/2

ERK1/2

pAKT (S473)

AKT

β actin

B

C

D

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

J Immunother Cancer

doi: 10.1136/jitc-2020-001496

9 2021; J Immunother Cancer, et al. Redin E